In this issue:
DAA-induced SVR: benefits in HCV advanced liver disease
Target TERT overexpression in HBV-related HCC?
Susceptibility of HCV genotype 4 subtype 4r to antivirals
Core mutations in HBV genotype F1b & HCC in Alaskan Natives
NS5A inhibits innate immune pathways during HCV infection
Real-world access to DAAs: very low in chronic HCV infection
SVR with DCV + SOF vs VEL/SOF in HCV GT2/3
Baseline RASs & 12 weeks of SOF/ VEL/VOX in DAA-experienced
HBV maintains a stable cccDNA pool
HBsAg seroclearance in adults with chronic HBV infection
Please login below to download this issue (PDF)